In lung cancer, cells which have high levels of the pro-apoptotic member BIM (protein and mRNA expression) or those with a low ratio of anti- to pro-apoptotic members following EGFR inhibitor treatment, were more sensitive to the agent [10, 11]. The gene discussed is EGFR; the disease is lung carcinoma.